Low-profile Danish biotech recruits Mikael Dolsten

Дата публикации: 13-08-2026 12:08:34

Основное содержимое страницы с новостью.

Danish biotech company Quantumcell has quietly assembled a heavyweight group of investors, including Novo Holdings and the Lundbeck Foundation. Following its multibillion-dollar deal with Sweden’s Alzecure, the company is now strengthening its ranks further – with Swedish executive Mikael Dolsten joining the board.

August 13, 2026 2:08 PM

Mikael Dolsten has been a board member of Quantumcell since the beginning of August, Medwatch reports, citing Denmark’s CVR business register.

He spent around 15 years as Pfizer’s global head of R&D, where he played a key role in the development of the company’s Covid-19 vaccine, among other things. He left the pharmaceutical giant in 2024.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Dansk doldis värvar Mikael Dolsten	0	10	13-08-2026
2	Ny finanschef till Biolamina	0	10	14-08-2026
3	Life Science Nordic launches – bringing Nordic life science news under one roof	0	5.62	17-08-2026
4	Lantheus challenges Eli Lilly with FDA-approved Alzheimer’s tracer	0	22.5	17-08-2026
5	Intel передаст технологии производства процессоров малоизвестному стартапу. У него даже нет сайта в интернете	0	10	30-07-2026
6	МТС купит компанию VisionLabs	0	0	13-12-2021
7		0	0	25-05-2026
8		0	0	05-05-2026
9		0	0	19-04-2026
10	Novartis is buying a U.K. cancer drug startup for up to $1.5 billion	0	7	06-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 26.67. Источник: www.magasinetpleje.dk.